Gene therapy: Theoretical and bioethical concepts

Archives of Medical Research

Volumn 34, Issue 4, 2003, Pages 247-268

  Smith, Kevin R ^a  

^a UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; OLIGONUCLEOTIDE; PACLITAXEL; RECOMBINANT DNA; RECOMBINANT RNA; TENIPOSIDE; VINBLASTINE; VINCRISTINE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLISTIC TRANSFORMATION; CARCINOMA; CELL NUCLEUS TRANSPLANTATION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DNA REPLICATION; DNA TRANSFER; DNA VECTOR; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; ELECTROPORATION; EMBRYO CELL; EMPHYSEMA; EMPIRICISM; ETHICS; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC DISORDER; GENETIC MANIPULATION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; GERM LINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MUTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATIENT CARE; PHENYLKETONURIA; RETINITIS PIGMENTOSA; RETROVIRUS; REVIEW; SAFETY; SICKLE CELL ANEMIA; SOMATIC CELL; SPERMATOZOON; STEM CELL; THEORY; TRANSGENE; TREATMENT INDICATION; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS GENOME;

EID: 0042830374     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(03)00070-5     Document Type: Review

References (211)

1. Smith K.R. Animal genetic manipulation - a utilitarian response. Bioethics. 16:(1):2002;55-71.
2. Lazo P.A., Tsichlis P.N. Biology and pathogenesis of retroviruses. Semin Oncol. 17:(3):1990;269-294.
3. Laufs S., Gentner B., Nagy K.Z., Jauch A., Benner A., Naundorf S., Kuehlcke K., Schiedlmeier B., Ho A.D., Zeller W.J., Fruehauf S. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood. 101:(6):2003;2191-2198.
4. Braas G., Searle P.F., Slater N.K.H., Lyddiatt A. Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation. 6:(4):1996;211-228.
5. Morgan R.A., Anderson W.F. Human gene therapy. Annu Rev Biochem. 62:1993;191-217.
6. Hu W.S., Pathak N.K. Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev. 52:(4):2000;493-511.
7. Miller D.G., Adam M.A., Miller A.D. Gene-transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 10:(8):1990;4239-4242.
8. Pannell D.J., Ellis J. Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol. 11:(4):2001;205-217.
9. Pannell D., Osborne C.S., Yao S.Y., Sukonnik T., Pasceri P., Karaiskakis A., Okano M., Li E., Lipshitz H.D., Ellis J. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J. 19:(21):2000;5884-5894.
10. Swindle C.S., Klug C.A. Mechanisms that regulate silencing of gene expression from retroviral vectors. J Hematother Stem Cell Res. 11:(3):2002;449-456.
11. Hoatlin M.E., Kozak S.L., Spiro C., Kabat D. Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques. J Mol Med. 73:(3):1995;113-120.
12. Vile R.G., Tuszynski A., Castleden S. Retroviral vectors - from laboratory tools to molecular medicines. Mol Biotechnol. 5:(2):1996;139-158.
13. Solly S.K., Trajcevski S., Frisen C., Holzer G.W., Nelson E., Clerc A., Abordo-Adesida E., Castro M., Lowenstein P., Klatzmann D. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 10:(1):2003;30-39.
14. Ellis J., Bernstein A. Gene targeting with retroviral vectors - recombination by gene conversion into regions of nonhomology. Mol Cell Biol. 9:(4):1989;1621-1627.
15. Weiss R.A., Weiss R.A., Teich N., Varmus H.E., Coffin J.M. Molecular biology of tumor viruses: RNA tumor viruses. 2nd ed. 1985; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
16. Temin H.M. Safety considerations in somatic gene-therapy of human-disease with retrovirus vectors. Hum Gene Ther. 1:(2):1990;111-123.
17. Cornetta K., Morgan R.A., Anderson W.F. Safety issues related to retroviral-mediated gene-transfer in humans. Hum Gene Ther. 2:(1):1991;5-14.
18. Gunter K.C., Khan A.S., Noguchi P. The safety of retroviral vectors. Hum Gene Ther. 4:(5):1993;643-645.
19. Buckley R.H. Gene therapy for SCID - a complication after remarkable progress. Lancet. 360:(9341):2002;1185-1186.
20. Kaiser J. Gene therapy - seeking the cause of induced leukemias in X-SCID trial. Science. 299:(5606):2003;495-495.
21. Gansbacher B., Gansbacher B., Danos O., Dickson G., Thielemans K., Cosset F.L., Deglon N., Dilber M.S., Galun E., Klatzmann D., Mavilio F., Taylor N. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) - Position statement from the European Society of Gene Therapy (ESGT). J Gene Med. 5:(1):2003;82-84.
22. Fox J.L. US authorities uphold suspension of SCID gene therapy. Nat Biotechnol. 21:(3):2003;217.
23. Tomanin R. Adenovirus-mediated gene transfer. Minerva Biotecnol. 9:(3):1997;117-122.
24. Lee M.G., Kremer E.J., Perricaudet M. Adenoviral vectors. Dickson G. Molecular and cell biology of human gene therapeutics. 1995; Chapman & Hall, London.
25. Bett A.J., Prevec L., Graham F.L. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol. 67:(10):1993;5911-5921.
26. Stratford-Perricaudet L.D., Makeh I., Perricaudet M., Briand P. Widespread long-term gene-transfer to mouse skeletal-muscles and heart. J Clin Invest. 90:(2):1992;626-630.
27. Reid T., Warren R., Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9:(12):2002;979-986.
28. Dettweiler U., Simon P. Points to consider for ethics committees in human gene therapy trials. Bioethics. 15:(5-6):2001;491-500.
29. Somia N., Verma I.M. Gene therapy: trials and tribulations. Nat Rev Genet. 1:(2):2000;91-99.
30. Lai C.M., Lai Y.K.Y., Rakoczy P.E. Adenovirus and adeno-associated virus vectors. DNA Cell Biol. 21:(12):2002;895-913.
31. Monahan P.E., Samulski R.J. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today. 6:(11):2000;433-440.
32. Carter P.J., Samulski R.J. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med. 6:(1):2000;17-27.
33. Netter H.J., Kajino K., Taylor J.M. Experimental transmission of human hepatitis-delta virus to the laboratory mouse. J Virol. 67:(6):1993;3357-3362.
34. Burton E.A., Wechuck J.B., Wendell S.K., Goins W.F., Fink D.J., Glorioso J.C. Multiple applications for replication-defective Herpes simplex virus vectors. Stem Cells. 19:(5):2001;358-377.
35. Stevens J.G. Human herpesviruses - a consideration of the latent state. Microbiol Rev. 53:(3):1989;318-332.
36. Lachmann R.H., Efstathiou S. The use of Herpes simplex virus-based vectors for gene delivery to the nervous system. Mol Med Today. 3:(9):1997;404-411.
37. Watwe R.M., Bellare J.R. Manufacture of liposomes. Curr Sci. 68:(7):1995;715-724.
38. Nicolau C., Legrand A., Grosse E. Liposomes as carriers for in vivo gene-transfer and expression. Methods Enzymol. 149:1987;157-176.
39. Ilies M.A., Balaban A.T. Recent developments in cationic lipid-mediated gene delivery and gene therapy. Expert Opin Ther Patients. 11:(11):2001; 1729-1752.
40. Felgner P.L. Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ther. 7:(15):1996;1791-1793.
41. Mahato R.I., Takakura Y., Hashida M. Nonviral vectors for in vivo gene delivery: physicochemical and pharmacokinetic considerations. Crit Rev Ther Drug Carrier Systems. 14:(2):1997;133-172.
42. Connor J., Yatvin M.B., Huang L. Ph-sensitive liposomes - acidinduced liposome fusion. Proc Natl Acad Sci USA. 81:(6):1984;1715-1718.
43. Lamb R.A. Paramyxovirus fusion - a hypothesis for changes. Virology. 197:(1):1993;1-11.
44. Tsuboniwa N., Morishita R., Hirano T., Fujimoto J., Furukawa S., Kikumori M., Okuyama A., Kaneda Y. Safety evaluation of hemagglutinating virus of Japan-artificial viral envelope liposomes in nonhuman primates. Hum Gene Ther. 12:(5):2001;469-487.
45. Yanagihara I., Kaneda Y., Invi K., Okada S. Liposome-mediated gene transfer. Dickson G. Molecular and cell biology of human gene therapeutics. 1995; Chapman & Hall, London.
46. Hyde S.C., Southern K.W., Gileadi U., Fitzjohn E.M., Mofford K.A., Waddell B.E., Gooi H.C., Goddard C.A., Hannavy K., Smyth S.E. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 7:(13):2000;1156-1165.
47. Stern M., Sorgi F., Hughes C., Caplen N.J., Browning J.E., Middleton P.G., Gruenert D.C., Farr S.J., Huang L., Geddes D.M. The effects of jet nebulisation on cationic liposome-mediated gene transfer in vitro. Gene Ther. 5:(5):1998;583-593.
48. Canonico A.E., Conary J.T., Meyrick B.O., Brigham K.L. Aerosol and intravenous transfection of human alpha-1-antitrypsin gene to lungs of rabbits. Am J Respir Cell Mol Biol. 10:(1):1994;24-29.
49. Losordo D.W., Vale P.R., Symes J.F., Dunnington C.H., Esakof D.D., Maysky M., Ashare A.B., Lathi K., Isner J.M. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF-1-6-5 as sole therapy for myocardial ischemia. Circulation. 98:(25):1998;2800-2804.
50. Dass C.R., Walker T.L., DeCruz E.E., Burton M.A. Cationic liposomes and gene therapy for solid tumors. Drug Delivery. 4:(3):1997;151-166.
51. Duzgunes N., Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Delivery Rev. 40:(1-2):1999;3-18.
52. Schaeferridder M., Wang Y., Hofschneider P.H. Liposomes as gene carriers - efficient transformation of mouse L-cells by thymidine kinase gene. Science. 215:(4529):1982;166-168.
53. Carroll M.W., Moss B. Poxviruses as expression vectors. Curr Opin Biotechnol. 8:(5):1997;573-577.
54. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 93:(21):1996;11341-11348.
55. Tiukinhoy S.D., Mahowald M.E., Shively V.P., Nagaraj A., Kane B., Klegerman M.E., MacDonald R.C., McPherson D.D., Matsumura J.S. Development of echogenic, plasmid-incorporated, tissue-targeted cationic liposomes that can be used for directed gene delivery. Invest Radiol. 35:2000;732-735.
56. Boulikas T. Nuclear localization signal peptides for the import of plasmid DNA in gene therapy. Int J Oncol. 10:(2):1997;301-309.
57. Smith K.R. Gene transfer in higher animals: theoretical considerations and key concepts. J Biotechnol. 99:(1):2002;1-22.
58. Lurquin P.F. Gene transfer by electroporation. Mol Biotechnol. 7:(1):1997;5-35.
59. Chang D.C., Saunders J.A., Chassy B.M., Sowers A.E. Overview of electroporation and electrofusion. Chang D.C. Guide to electroporation and electrofusion. 1992; 1-6 Academic Press, San Diego, CA, USA.
60. Potter H., Cooke S.W.F. Gene transfer into adherent cells growing on microbeads. Chang D.C. Guide to electroporation and electrofusion. 1992; 201-208 Academic Press, San Diego, CA, USA.
61. Hatada S., Nikkuni K., Bentley S.A., Kirby S., Smithies O. Gene correction in hematopoietic progenitor cells by homologous recombination. Proc Natl Acad Sci USA. 97:(25):2000;13807-13811.
62. Swartz M., Eberhart J., Mastick G.S., Krull C.E. Sparking new frontiers: using in vivo electroporation for genetic manipulations. Dev Biol. 233:(1):2001;13-21.
63. Hofmann G.A., Dev S.B., Nanda G.S., Rabussay D. Electroporation therapy of solid tumors. Crit Rev Ther Drug Carrier Syst. 16:(6):1999;523-569.
64. Herweijer H., Wolff J.A. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther. 10:(6):2003;453-458.
65. Klein T.M., Arentzen R., Lewis P.A., Fitzpatrick McElligott S. Transformation of microbes, plants and animals by particle bombardment. Biotechnology. 10:(3):1992;286-291.
66. Cheng L., Ziegelhoffer P.R., Yang N.S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA. 90:(10):1993;4455-4459.
67. Gainer A.L., Korbutt G.S., Rajotte R.V., Warnock G.L., Elliott J.F. Successful biolistic transformation of mouse pancreatic islets while preserving cellular function. Transplantation. 61:(11):1996;1567-1571.
68. Mahvi D.M., Sheehy M.J., Yang N.S. DNA cancer vaccines: a gene gun approach. Immunol Cell Biol. 75:(5):1997;456-460.
69. Smith K. Theoretical mechanisms in targeted and random integration of transgene DNA. Reprod Nutr Dev. 41:(6):2001;465-485.
70. Kirn D., Niculescu-Duvaz I., Hallden G., Springer C.J. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med. 8:(4):2002;S68-S73.
71. Mullen C.A. Metabolic suicide genes in gene-therapy. Pharmacol Ther. 63:(2):1994;199-207.
72. Crooke S.T., Bennett C.F. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 36:1996;107-129.
73. Cavazzana-Calvo M., Hacein-Bey S., Basile C.D., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Le Deist F., Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:(5466):2000;669-672.
74. Otsu M., Candotti F. Gene therapy in infants with severe combined immunodeficiency. Biodrugs. 16:(4):2002;229-239.
75. Cavazzana-Calvo M., Hacein-Bey S., Yates F., de Villartay J.P., Le Deist F., Fischer A. Gene therapy of severe combined immunodeficiencies. J Gene Med. 3:(3):2001;201-206.
76. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., Morecki S., Andolfi G., Tabucchi A., Carlucci F., Marinello E., Cattaneo F., Vai S., Servida P., Miniero R., Roncarolo M.G., Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:(5577):2002;2410-2413.
77. Hoogerbrugge P.M., Blessing J.J.H., Vossen J.M., Valerio D. Treatment of adenosine deaminase deficiency. Biodrugs. 9:(2):1998;87-93.
78. Roth D.A., Tawa N.E., O'Brien J.M., Treco D.A., Selden R.F. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia, A. N Engl J Med. 344:(23):2001;1735-1742.
79. Kay M.A., Manno C.S., Ragni M.V., Larson P.J., Couto L.B., McClelland A., Glader B., Chew A.J., Tai S.J., Herzog R.W., Arruda V., Johnson F., Scallan C., Skarsgard E., Flake A.W., High K.A. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 24:(3):2000;257-261.
80. High K.A. Adeno-associated virus-mediated gene transfer for hemophilia B. Int J Hematol. 76:(4):2002;310-318.
81. Geddes D., Alton E. Cystic fibrosis clinical trials. Adv Drug Delivery Rev. 8730:(1-3):1998;205-217.
82. Boyd A.C. Gene therapy for cystic fibrosis. Expert Opin Ther Patents. 11:(1):2001;1-15.
83. Ferrari S., Geddes D.M., Alton E. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Delivery Rev. 54:(11):2002;1373-1393.
84. Griesenbach U., Ferrari S., Geddes D.M., Alton E. Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 9:(20):2002;1344-1350.
85. Davies J.C., Geddes D.M., Alton E. Gene therapy for cystic fibrosis. J Gene Med. 3:(5):2001;409-417.
86. Vadolas J., Williamson R., Ioannou P.A. Gene therapy for inherited lung disorders: an insight into pulmonary defence. Pulm Pharmacol Ther. 15:(1):2002;61-72.
87. Gautam A., Waldrep J.C., Densmore C.L. Aerosol gene therapy. Mol Biotechnol. 23:(1):2003;51-60.
88. Chamberlain J.S. Gene therapy of muscular dystrophy. Hum Mol Genet. 11:(20):2002;2355-2362.
89. Stecenko A.A., Brigham K.L. Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Ther. 10:(2):2003;95-99.
90. Eisensmith R.C., Kuzmin A.I., Krougliak V.A. Prospects for the treatment of phenylketonuria by gene therapy. Ment Retard Dev Disab Res Rev. 5:(2):1999;136-143.
91. Dejneka N.S., Bennett J. Gene therapy and retinitis pigmentosa: advances and future challenges. Bioessays. 23:(7):2001;662-668.
92. Pawliuk R., Westerman K.A., Fabry M.E., Payen E., Tighe R., Bouhassira E.E., Acharya S.A., Ellis J., London I.M., Eaves C.J., Humphries R.K., Beuzard Y., Nagel R.L., Leboulch P. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 294:(5550):2001;2368-2371.
93. Coutelle C., Rodeck C. On the scientific and ethical issues of fetal somatic gene therapy. Gene Ther. 9:(11):2002;670-673.
94. Flake A.W. Genetic therapies for the fetus. Clin Obstet Gynecol. 45:(3):2002;684-696.
95. Quarck R., Holvoet P. Restenosis and gene therapy. Expert Opin Biol Ther. 1:(1):2001;79-91.
96. Rutanen J.J., Markkanen J., Yla-Herttuala S. Gene therapy for restenosis - current status. Drugs. 62:(11):2002;1575-1585.
97. Freedman S.B. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol. 13:(6):2002;653-661.
98. Blesch A., Tuszynski M. Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Clin Neurosci. 3:(5):1996;268-274.
99. Factor P. Gene therapy for asthma. Mol Ther. 7:(2):2003;148-152.
100. Martino G., Furlan R., Comi G., Adorini L. The ependymal route to the CNS: an emerging gene-therapy approach for MS. Trends Immunol. 22:(9):2001;483-490.
101. Demeterco C., Levine F. Gene therapy for diabetes. Front Biosci. 6:2001;D175-D191.
102. Lesch K.P. Gene transfer to the brain: emerging therapeutic strategy in psychiatry? Biol Psychiatry. 45:(3):1999;247-253.
103. Heo D.S. Progress and limitations in cancer gene therapy. Genet Med. 4:(6):2002;52S-55S.
104. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 1:(2):2001;130-141.
105. Wadhwa P.D., Zielske S.P., Roth J.C., Ballas C.B., Bowman J.E., Gerson S.L. Cancer gene therapy: scientific basis. Annu Rev Med. 53:2002;437-452.
106. Greco O., Scott S.D., Marples B., Dachs G.U. Cancer gene therapy: delivery, delivery, delivery. Front Biosci. 7:2002;D1516-D1524.
107. Bonnekoh B., Greenhalgh D.A., Chen S.H., Block A., Rich S.S., Krieg T., Woo S.L.C., Roop D.R. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defense in the B16 melanoma model. J Invest Dermatol. 110:(6):1998;867-871.
108. Ram Z., Culver K.W., Walbridge S., Frank J.A., Blaese R.M., Oldfield E.H. Toxicity studies of retroviral-mediated gene-transfer for the treatment of brain-tumors. J Neurosurg. 79:(3):1993;400-407.
109. Fong T.C., Sauter S.L., Ibanez C.E., Sheridan P.L., Jolly D.J. The use and development of retroviral vectors to deliver cytokine genes for cancer therapy. Crit Rev Ther Drug Carrier Syst. 17:(1):2000;1-60.
110. Wildner O. Oncolytic viruses as therapeutic agents. Ann Med. 33:(5):2001;291-304.
111. Tamiya T., Wei M.X., Chase M., Ono Y., Lee F., Breakefield X.O., Chiocca E.A. Transgene inheritance and retroviral infection contribute to the efficiency of gene-expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther. 2:(8):1995;531-538.
112. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene-transfer with retroviral vector producer cells for treatment of experimental brain-tumors. Science. 256:(5063):1992;1550-1552.
113. Long Z.F., Li L.P., Grooms T., Lockey C., Nader K., Mychovsky I., Mueller S., Burimski I., Ryan P., Kikuchi G., Ennist D., Marcus S., Otto E., McGarrity G. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther. 9:(8):1998;1165-1172.
114. Packer R.J., Raffel C., Villablanca J.G., Tonn J.C., Burdach S.E., Burger K., LaFond D., McComb J.G., Cogen P.H., Vezina G., Kapcala L.P. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vectorproducer cells followed by intravenous ganciclovir administration. J Neurosurg. 92:(2):2000;249-254.
115. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 11:(17):2000;2389-2401.
116. Ram Z., Culver K.W., Oshiro E.M., Viola J.J., DeVroom H.L., Otto E., Long Z.F., Chiang Y., McGarrity G.E.J., Muul L.M., Katz D., Blaese R.M., Oldfield E.H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 3:(12):1997;1354-1361.
117. Barzon L., Bonaguro R., Castagliuolo I., Chilosi M., Franchin E., Del Vecchio C., Giaretta I., Boscaro M., Palu G. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol. 148:(1):2003;73-80.
118. Lee C.T., Park K.H., Adachi Y., Seol J.Y., Yoo C.G., Kim Y.W., Han S.K., Shim Y.S., Coffee K., Dikov M.M., Carbone D.P. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther. 10:(1):2003;57-63.
119. Satoh T., Timme T.L., Saika T., Ebara S., Yang G., Wang J.X., Ren C.Z., Kusaka N., Mouraviev V., Thompson T.C. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther. 14:(2):2003;91-101.
120. Ebara S., Shimura S., Nasu Y., Kaku H., Kumon H., Yang G., Wang J., Timme T.L., Aguilar-Córdova E., Thompson T.C. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prost Cancer Prost Dis. 5:(4):2002;316-325.
121. Zhang X.Q., Multani A.S., Zhou J.H., Shay J.W., McConkey D., Dong L., Kim C.S., Rosser C.J., Pathak S., Benedict W.F. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res. 63:(4):2003;760-765.
122. Kubo H., Gardner T.A., Wada Y., Koeneman K.S., Gotoh A., Yang L., Kao C.H., Lim S.D., Amin M.B., Yang H., Black M.E., Matsubara S., Nakagawa M., Gillenwater J.Y., Zhau H.Y.E., Chung L.W.K. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 14:(3):2003;227-241.
123. Rots M.G., Curiel D.T., Gerritsen W.R., Haisma H.J. Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J Controlled Release. 87:(1-3):2003;159-165.
124. Dirven C.M.F., van Beusechem V.W., Lamfers M.L.M., Grill J., Gerritsen W.R., Vandertop W.P. Oncolytic adenoviruses for treatment of brain tumours. Expert Opin Biol Ther. 2:(8):2002;943-952.
125. Hemminki A., Alvarez R.D. Adenoviruses in oncology - a viable option? Biodrugs. 16:(2):2002;77-87.
126. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8:(2):2001;89-98.
127. Lambin P., Nuyts S., Landuyt W., Theys J., De Bruijn E., Anne J., Van Mellaert L., Fowler J. The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase. Int J Rad Biol. 76:(3):2000;285-293.
128. Kato H., Koshida K., Yokoyama K., Mizokami A., Namiki M. Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study. Int J Urol. 9:(10):2002;567-576.
129. Quist S.R., Wang-Gohrke S., Runnebaum I.B. Cooperative effects of adenoviral p53 gene therapy and paclitaxel/carboplatin chemotherapy in ovarian cancer cells. Int J Cancer. 100:2002;329.
130. Li Y.M., Okegawa T., Lombardi D.P., Frenkel E.P., Hsieh J.T. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. J Urol. 167:(1):2002;339-346.
131. Ueno M., Koyama F., Yamada Y., Fujimoto H., Takayama T., Kamada K., Naito A., Mukogawai S.H.T., Hamada H. Tumor-specific chemo-radio-gene therapy for colorectal cancer cells using adenovirus vector expressing the cytosine deaminase gene. Anticancer Res. 21:(4A):2001;2601-2608.
132. Nicholas T.W., Read S.B., Burrows F.J., Kruse C.A. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol. 18:(2):2003;495-507.
133. Mesnil M., Yamasaki H. Bystander effect in suicide gene therapy of cancers. Biogen Amines. 15:(1):1999;39-52.
134. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gapjunctional intercellular communication. Cancer Res. 60:(15):2000;3989-3999.
135. Im S.A., Kim J.S., Gómez-Manzano C., Fueyo J., Liu T.J., Cho M.S., Seong C.M., Lee S.N., Hong Y.K., Yung W.K.A. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer. 84:(9):2001;1252-1257.
136. Gleave M., Miyake H., Zangemeister-Wittke U., Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev. 21:(1):2002;79-92.
137. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol. 3:(11):2002;672-683.
138. Wright L., Kearney P. Current status of ribozymes as gene therapy agents for cancer. Cancer Invest. 19:(5):2001;495-509.
139. Turner P.C. Ribozymes - their design and use in cancer. Adv Exp Med Biol. 465:2000;303-318.
140. Cho-Chung Y.S. Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic. Expert Opin Ther Patents. 10:(11):2000;1711-1724.
141. Vásquez K.M., Wilson J.H. Triplex-directed modification of genes and gene activity. Trends Biochem Sci. 23:(1):1998;4-9.
142. Aoki Y., Cioca D.P., Oidaira H., Kamiya J., Kiyosawa K. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exper Pharmacol Physiol. 30:(12):2003;96-102.
143. Meng R.D., El-Deiry W.S. Tumor suppressor gene therapy for cancer: from the bench to the clinic. Drug Resistance Updates. 1:(3):1998;205-210.
144. Nielsen L.L., Maneval D.C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5:(1):1998;52-63.
145. Gleich L.L. Gene therapy for head and neck cancer. Laryngoscope. 110:(5):2000;708-726.
146. Swisher S.G., Roth J.A., Komaki R., Gu J., Lee J.J., Hicks M., Ro J.Y., Hong W.K., Merritt J.A., Ahrar K., Atkinson N.E., Correa A.M., Dolormente M., Dreiling L., El-Naggar A.K., Fossella F., Francisco R., Glisson B., Grammer S., Herbst R., Huaringa A., Kemp B., Khuri F.R., Kurie J.M., Liao Z.X., McDonnell T.J., Morice R., Morello F., Munden R., Papadimitrakopoulou V., Pisters K.M.W., Putnam J.B., Sarabia A.J., Shelton T., Stevens C., Shin D.M., Smythe W.R., Vaporciyan A.A., Walsh G.L., Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 9:(1):2003;93-101.
147. Schuler M., Herrmann R., De Greve J.L.P., Stewart A.K., Gatzemeier U., Stewart D.J., Laufman L., Gralla R., Kuball J., Buhl R., Heussel C.P., Kommoss F., Perruchoud A.P., Shepherd F.A., Fritz M.A., Horowitz J.A., Huber C., Rochlitz C. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol. 19:(6):2001;1750-1758.
148. Buller R.E., Runnebaum I.B., Karlan B.Y., Horowitz J.A., Shahin M., Buekers T., Petrauskas S., Kreienberg R., Slamon D., Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9:(7):2002;553-566.
149. Pagliaro L.C. Gene therapy for bladder cancer. World J Urol. 18:(2):2000;148-151.
150. Habib N.A., Hodgson H.J.F., Lemoine N., Pignatelli M. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumors. Hum Gene Ther. 10:(12):1999;2019-2034.
151. Kasuya H., Nomoto S., Nakao A. The potential of gene therapy in the treatment of pancreatic cancer. Drugs Today. 38:(7):2002;457-464.
152. Spencer H.T., Sleep S.E.H., Rehg J.E., Blakley R.L., Sorrentino B.P.A. Gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood. 87:(6):1996;2579-2587.
153. Carpinteiro A., Peinert S., Ostertag W., Zander A.R., Hossfeld D.K., Kuhlcke K., Eckert H.G., Baum C., Hegewisch-Becker S. Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. Int J Cancer. 98:(5):2002;785-792.
154. Knipper R., Kuehlcke K., Schiedlmeier B., Hildinger M., Lindemann C., Schilz A.J., Fauser A.A., Fruehauf S., Zeller W.J., Ostertag W., Eckert H.G., Baum C. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Ther. 8:(3):2001;239-246.
155. Schilz A.J., Schiedlmeier B., Kuhlcke K., Fruehauf S., Lindemann C., Zeller W.J., Grez M., Fauser A.A., Baum C., Eckert H.G. MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions. Mol Ther. 2:(6):2000;609-618.
156. Deisseroth A.B., Holmes F., Hortobagyi G., Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Hum Gene Ther. 7:(3):1996;401-416.
157. Hesdorffer C., Ayello J., Ward M., Kaubisch A., Vahdat L., Balmaceda C., Garrett T., Fetell M., Reiss R., Bank A., Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 16:(1):1998;165-172.
158. Hanania E.G., Giles R.E., Kavanagh J., Ellerson D., Wang T., Zu Z., Calvert L., Haley T., Hamer J., Berenson R., Heimfeld S., Rahman Z., Champlin R., Deisseroth A.B. The human multiple drug resistance gene (MDR-1) is used to confer chemoprotection upon hematopoietic progenitor cells in a clinical gene therapy trial setting for ovarian and breast cancer treatment. J Invest Med. 44:(3):1996;A314-A314.
159. Parney I.F., Chang L.J. Cancer immunogene therapy: a review. J Biomed Sci. 10:(1):2003;37-43.
160. Biagi E., Rousseau R.F., Yvon E., Vigouroux S., Dotti G., Brenner M.K. Cancer vaccines: dream, reality, or nightmare? Clin Exp Med. 2:(3):2002;109-118.
161. Bunnell B.A., Morgan R.A. Gene therapy for infectious diseases. Clin Microbiol Rev. 11:(1):1998;42-56.
162. Mautino M.R., Morgan R.A. Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care Stud. 16:(1):2002;11-26.
163. Statham V.S., Morgan R.A. Gene therapy clinical trials for HIV. Curr Opin Mol Ther. 1:(4):1999;430-436.
164. Tarner I.H., Fathman C.G. The potential for gene therapy in the treatment of autoimmune disease. Clin Immunol. 104:(3):2002;204-216.
165. Gould D.J., Favorov P. Vectors for the treatment of autoimmune disease. Gene Ther. 10:(10):2003;912-927.
166. Yang K., Clifton G.L., Hayes R.L. Gene therapy for central nervous system injury: the use of cationic liposomes. J Neurotrauma. 14:(5):1997;281-297.
167. Blits B., Boer G.J., Verhaagen J. Pharmacological, cell, and gene therapy strategies to promote spinal cord regeneration. Cell Transplant. 11:(6):2002;593-613.
168. Palmer G., Pascher A., Gouze E., Gouze J.N., Betz O., Spector M., Robbins P.D., Evans C.H., Ghivizzani S.C. Development of gene-based therapies for cartilage repair. Crit Rev Eukaryot Gene Express. 12:(4):2002;259-273.
169. Kaplitt M.G., Darakachiev B., During M.J. Prospects for gene therapy in pediatric neurosurgery. Pediatr Neurosurg. 28:(1):1998;3-14.
170. Porada C.D., Tran N., Eglitis M., Moen R.C., Troutman L., Flake A.W., Zhao Y., Anderson W.F., Zanjani E.D. In utero gene therapy: transfer and long-term expression of the bacterial neo(Gamma) gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Hum Gene Ther. 9:(11):1998;1571-1585.
171. Pan D., Gunther R., Duan W.M., Wendell S., Kaemmerer W., Kafri T., Verma I.M., Whitley C.B. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther. 6:(1):2002;19-29.
172. Arruda V.R., Fields P.A., Milner R., Wainwright L., De Miguel M.P., Donovan P.J., Herzog R.W., Nichols T.C., Biegel J.A., Razavi M., Dake M., Huff D., Flake A.W., Couto L., Kay M.A., High K.A. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther. 4:(6):2001;586-592.
173. Peters A., Drumm J., Ferrell C., Roth D.A., Roth D.M., McCaman M., Novak P.L., Friedman J., Engler R., Braun R.E. Absence of germline infection in male mice following intraventricular injection of adenovirus. Mol Ther. 4:(6):2001;603-613.
174. Themis M., Schneider H., Kiserud T., Cook T., Adebakin S., Jezzard S., Forbes S., Hanson M., Pavirani A., Rodeck C., Coutelle C. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Ther. 6:(7):1999;1239-1248.
175. Anderson W.F. Human-gene therapy - scientific and ethical considerations. J Med Philos. 10:(3):1985;275-291.
176. Walters L., Palmer J.G. The ethics of human gene therapy. 1997; Oxford University Press, Oxford, UK.
177. Jaenisch R. Transgenic animals. Science. 240:(4858):1988;1468-1474.
178. Boyd A.L., Samid D. Molecular biology of transgenic animals. J Anim Sci. 71:(3/Suppl):1993;1.
179. Whitelaw C.B.A., Springbett A.J., Webster J., Clark J. The majority of G-0 transgenic mice are derived from mosaic embryos. Transgen Res. 2:(1):1993;29-32.
180. Brinster R.L., Braun R.E., Lo D., Avarbock M.R., Oram F., Palmiter R.D. Targeted correction of a major histocompatibility class-II E-alpha gene by DNA microinjected into mouse eggs. Proc Natl Acad Sci USA. 86:(18):1989;7087-7091.
181. Rulicke T., Hubscher U. Germ line transformation of mammals by pronuclear microinjection. Exper Physiol. 85:(6):2000;589-601.
182. Kistner A., Gossen M., Zimmermann F., Jerecic J., Ullmer C., Lubbert H., Bujard H. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA. 93:(20):1996;10933-10938.
183. Wallace H., Ledent C., Vassart G., Bishop J.O., Alshawi R. Specific ablation of thyroid-follicle cells in adult transgenic mice. Endocrinology. 129:(6):1991;3217-3226.
184. Niemann H., Halter R., Carnwath J.W., Herrmann D., Lemme E., Paul D. Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep. Transgen Res. 8:(3):1999;237-247.
185. Gordon J.W., Scangos G.A., Plotkin D.J., Barbosa J.A., Ruddle F.H. Genetic-transformation of mouse embryos by micro-injection of purified DNA. Proc Natl Acad Sci USA. 77:(12):1980;7380-7384.
186. Hogan B., Beddington R., Constantin F., Lacy E. Manipulating the mouse embryo. 1994; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.
187. Torres M. The use of embryonic stem cells for the genetic manipulation of the mouse. Curr Topics Dev Biol. 36:1998;99-114.
188. Pirity M., Hadjantonakis A.K., Nagy A. Embryonic stem cells, creating transgenic animals. Methods Cell Biol. 57:1998;279-293.
189. Metzger D., Feil R. Engineering the mouse genome by site-specific recombination. Curr Opin Biotechnol. 10:(5):1999;470-476.
190. Muller U. Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. Mech Dev. 82:(1-2):1999;3-21.
191. Wilmut I. Viable offspring derived from fetal and adult mammalian cells, in societal, medical and ethical implications of cloning. 1997; Office for Official Publications of the European Communities, London.
192. Schnieke A.E., Kind A.J., Ritchie W.A., Mycock K., Scott A.R., Ritchie M., Wilmut I., Colman A., Campbell K.H.S. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science. 278:(5346):1997;2130-2133.
193. Campbell K.H.S., McWhir J., Ritchie W.A., Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature. 380:(6569):1996;64-66.
194. Tsunoda Y., Kato Y. The recent progress on nuclear transfer in mammals. Zool Sci. 17:(9):2000;1177-1184.
195. Wolf E., Schernthaner W., Zakhartchenko V., Prelle K., Stojkovic M., Brem G. Transgenic technology in farm animals - progress and perspectives. Exp Physiol. 85:(6):2000;615-625.
196. Clark A.J., Burl S., Denning C., Dickinson P. Gene targeting in livestock: a preview. Transgen Res. 9:(4-5):2000;263-275.
197. McCreath K.J., Howcroft J., Campbell K.H.S., Colman A., Schnieke A.E., Kind A.J. Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature. 405:(6790):2000;1066-1069.
198. Lai L.X., Kolber-Simonds D., Park K.W., Cheong H.T., Greenstein J.L., Im G.S., Samuel M., Bonk A., Rieke A., Day B.N., Murphy C.N., Carter D.B., Hawley R.J., Prather R.S. Production of alpha-1, 3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science. 295:(5557):2002;1089-1092.
199. Smith L.C., Bordignon V., Babkine M., Fecteau G., Keefer C. Benefits and problems with cloning animals. Can Vet J. 41:(12):2000;919-924.
200. Renard J.P., Zhou Q., LeBourhis D., Chavatte-Palmer P., Hue I., Heyman Y., Vignon X. Nuclear transfer technologies: between successes and doubts. Theriogenology. 57:(1):2002;203-222.
201. Kono T. Influence of epigenetic changes during oocyte growth on nuclear reprogramming after nuclear transfer. Reprod Fertil Dev. 10:(7-8):1998;593-598.
202. Rideout W.M., Eggan K., Jaenisch R. Nuclear cloning and epigenetic reprogramming of the genome. Science. 293:(5532):2001;1093-1098.
203. Wakayama T., Yanagimachi R. Mouse cloning with nucleus donor cells of different age and type. Mol Reprod Dev. 58:(4):2001;376-383.
204. Smith K.R. Sperm cell mediated transgenesis. Anim Biotechnol. 10:(1/2):1999;1-14.
205. Huguet E., Esponda P. Foreign DNA introduced into the vas deferens is gained by mammalian spermatozoa. Mol Reprod Dev. 51:(1):1998;42-52.
206. Huguet E., Esponda P. Generation of genetically modified mice by spermatozoa transfection in vivo: preliminary results. Mol Reprod Dev. 56:(2; Suppl 1):2000;243-247.
207. Sato M., Gotoh K., Kimura M. Sperm-mediated gene transfer by direct injection of foreign DNA into mouse testis. Transgenics. 2:(4):1999;357-369.
208. Resnik B., Langer P.J. Human germline gene therapy reconsidered. Hum Gene Ther. 12:(11):2001;1449-1458.
209. Resnik D., Steinkraus H.B., Langer P.J. Human germline gene therapy: scientific, moral and political issues. 1999; R.G. Landes Co. Austin, TX, USA.
210. Frankel M.S., Chapman A.R. Human inheritable genetic modifications: assessing scientific, ethical, religious and policy issues (report). 2000; American Association for the Advancement of Science, Washington, Washington, D.C., USA.
211. Stock G., Campbell J. Engineering the human germline. 1999; Oxford University Press, Oxford, UK.